Table S1 Genetic and clinicopathologic characteristics of 16 patients with available data

Patient ID	Histology	Genetic alterations	PD-L1 TPS (%)	TTF-1 Expression	Tumor Differentiation
01	Squamous cell carcinoma	BRAF, TP53	–	–	Poorly differentiated
02	Squamous cell carcinoma	None	–	–	Moderately differentiated
03	Adenocarcinoma	KRAS	–	–	Poorly differentiated
04	Adenocarcinoma	ERBB2	–	–	Moderately differentiated
05	Adenocarcinoma	EGFR Exon 21	–	–	Well-differentiated
06	Adenocarcinoma	EGFR Exon 21	–	–	Well-differentiated
07	Adenocarcinoma	EGFR Exon 19	–	–	Well-differentiated
08	Adenocarcinoma	EGFR Exon 21	–	–	Well-differentiated
09	Adenocarcinoma	STK11, TP53	–	–	Poorly differentiated
10	Adenocarcinoma	ALK	–	–	Well-differentiated
11	Adenocarcinoma	ALK	–	+++	Well-differentiated
12	Adenocarcinoma	EGFR Exon 21	–	–	Well-differentiated
13	Adenocarcinoma	KRAS	–	–	Poorly differentiated
14	Adenocarcinoma	None	35%	–	Moderately differentiated
15	Adenocarcinoma	None	–	+	Poorly differentiated
16	Adenocarcinoma	EGFR Exon 21	–	–	Well-differentiated

Table S2 One-year mortality by stage of LC and relationship with LDH and albumin

Variable	NSCLC			SCLC		
	≤ Stage IIIA	> Stage IIIA	P value	Limited stage	Extensive stage	P value
One-year mortality	11/42 (26.2)	39/78 (50.0)	0.02	2/4 (50.0)	16/19 (84.2)	0.19
LDH (U/L)	276.17±161.49	270.20 ±114.92	0.80	358.90±329.29	280.00±115.65	0.41
Albumin (g/L)	37.41±3.94	36.90±5.11	0.52	38.9±63.71	42.27±10.32	0.13